Form 4: Pacira BioSciences Director Equity Grant Disclosure

Director Laura Brege received a grant of 6,405 restricted stock units and 10,891 stock options as part of annual compensation.

Summary

• Director Laura Brege was granted 6,405 restricted stock units (RSUs) on June 10, 2026.
• Director Laura Brege was granted 10,891 stock options with an exercise price of $23.42 on June 10, 2026.
• Both the RSUs and the stock options are subject to a one-year vesting period, becoming fully exercisable on June 10, 2027.
• Following these transactions, the director's total beneficial ownership of common stock is 30,120 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant change in company strategy or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard retention mechanism via one-year cliff vesting requirements.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though standard for corporate governance.

Risks

• Market price volatility affecting the value of the granted options.
• Dependence on continued service for the vesting of equity awards.

Future Outlook

The equity grants are subject to continued service through June 10, 2027, at which point the securities will vest.

Management Comments

• The grants represent standard annual compensation for board service.

Industry Context

StockSavvy.ai notes that this filing reflects standard corporate governance practices for mid-cap biotechnology firms, where board members are compensated through a mix of cash and equity to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The use of one-year cliff vesting for director equity is consistent with standard practices among U.S. life sciences companies.
• The grant size is typical for non-employee directors in the biotechnology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from new equity issuance.
• Director: Increased financial stake in the company's performance.

Next Steps

• Vesting of equity awards on June 10, 2027.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, Director Compensation, Equity Grant, Insider Ownership